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C3 nephritic factors are autoantibodies that prolong the half-
life or prevent regulation of the alternative pathway C3
convertase, resulting in uncontrolled complement activation.
They are strongly associated with renal disease but their role
in pathogenesis remains controversial. Here we optimized
and compared a panel of assays to identify and interrogate
nephritic factor activities. Of 101 patients with histologic or
clinically evident disease, 48 were positive in some or all
assays. In the presence of properdin, binding of autoantibody
was detected in 39 samples and convertase stabilization was
detected in 36. Forty-two of 48 nephritic factors tested
prevented convertase decay by factor H, and most of these
by decay accelerating factor (28) and complement receptor 1
(34). Representative properdin-independent nephritic factors
had no effect on C5 cleavage and terminal pathway activity,
while properdin-dependent nephritic factors enhanced
activity. Biacore analysis of four purified IgG samples
confirmed resistance to decay and showed that properdin-
independent nephritic factors increased convertase half-life
over 50-fold, whereas properdin-dependent nephritic factors
increased the half-life 10- to 20-fold and also increased
activity of the C3 convertase up to 10-fold. Thus, our study
provides a rational approach to detect and characterize
nephritic factors in patients.
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Complement is a key component of innate immunity.1 The
complement alternative pathway (AP) is critical for ampli-
fication; the key amplifying enzyme is the AP C3 convertase,
C3bBb. C3b, surface-bound or in fluid phase, binds factor B
(fB) in a Mg2þ -dependent manner and presents it for
cleavage by factor D (fD). The enzyme, Bb, remains attached
to C3b and cleaves more C3 to C3b, driving amplification.
C3bBb is naturally labile, dissociating with a half-life of 90 s
at 37 1C; binding of properdin extends half-life 10-fold.2
Newly formed C3b binds indiscriminately pathogens and
host cells; damage to self is restricted by complement regula-
tors in the fluid phase (factor H; fH) and on membranes
(decay accelerating factor, DAF; membrane cofactor protein;
CR1, complement receptor 1) that accelerate decay of C3bBb
(fH, DAF, CR1) or are cofactors for inactivation of C3b by
factor I (fH, membrane cofactor protein, CR1).3,4
Uncontrolled AP activation following overwhelming
infection or polytrauma contributes to the systemic inflam-
matory response syndrome.5 AP control is also compromised
by complement protein mutations or by autoantibodies that
stabilize the convertase.6–8 Autoantibodies targeting the AP
C3 convertase, C3 nephritic factors (C3NeF), are associated
with renal disease, present in 50% of patients with membra-
noproliferative glomerulonephritis Types I and III, and 80%
with dense deposit disease (DDD; previously named mem-
branoproliferative glomerulonephritis Type II).9,10 C3NeF are
also associated with partial lipodystrophy11 and, rarely,
poststreptococcal glomerulonephritis, systemic lupus erythe-
matosus, and meningococcal meningitis.11–13 C3NeF are occa-
sional findings in healthy individuals, provoking the suggestion
that they are part of the normal immune repertoire and
causing some to question whether C3NeF are causal for the
associated pathologies or merely markers of disease.14–17
Numerous studies have explored mechanisms of action
of C3NeF; all bind C3bBb while some also bind C3b or
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Bb alone.18 C3NeF stabilize the convertase, markedly
increasing half-life,19 and inhibit accelerated decay mediated
by fH, DAF, and CR1, although reported efficiency of
inhibition differed between studies.20–22 Some reported a
requirement for properdin for C3NeF stabilization of C3bBb,
separating C3NeF into properdin-dependent and -indepen-
dent groups with different effects in vivo.23
Despite strong disease association and effects on C3
convertase stability, the pathogenic significance of C3NeF
is uncertain because C3NeF activity correlates poorly with
C3 consumption and disease progression, and C3NeF are
found in healthy individuals.15 There is further uncertainty
regarding whether C3NeF are primary causes of disease or
secondary consequences and modifiers of the disease process.
These uncertainties are exacerbated by lack of robust,
reproducible assays. Few routine laboratories measure
C3NeF, and methods are variable, technically complex, and
lack standardization and appropriate quality control. These
problems are exacerbated because C3NeF are heterogeneous
between and even within individuals, and some assays
may detect only subsets of C3NeF. Some C3NeF additionally
stabilize the C5 convertase, causing C5 consumption and
terminal pathway activation, sometimes without significantly
activating C3,23 these are easily missed using C3 cleavage
assays;24 these C3NeF may require properdin in the con-
vertase.23
We set out to define a suite of assays that enabled
reproducible detection of all C3NeF in patient samples. For
a subset of the identified C3NeF, we performed in-depth
analyses of target binding, convertase stabilization, dysregu-
lation, and escape from decay acceleration. The assays
described are optimized to permit reproduction in other
laboratories. Adoption into routine use will improve the
capacity to diagnose and monitor patients with C3NeF-
associated diseases.
RESULTS
Detection of C3NeF in patient samples
Serum samples were available from 101 patients presenting
with histological and/or clinical evidence of DDD (480%),
membranoproliferative glomerulonephritis I/III, or, rarely,
other renal pathologies, and proven AP activation (low C3,
fB), and 25 healthy controls (Table 1). Samples were screened
for C3NeF using the five assays described in Methods: C3
convertase stabilization enzyme-linked immunosorbent assay
(ELISA; COS), C3 convertase with added properdin ELISA
(COS-P), C3NeF immunoglobulin G (IgG)-binding ELISA
(COIg), hemolytic assay (HA), and fluid-phase C3 cleavage
assay (FPC). For some samples, insufficient volume or other
technical matters prevented analysis in HA and/or FPC
assays. All assays were repeated at least twice.
The ELISA measures the capacity of C3NeF to bind
(COIg) and stabilize (COS and COS-P) the AP C3 conver-
tase, whereas activity assays measure C3 cleavage by C3NeF-
stabilized convertase either directly (FPC) or by developing
hemolysis (HA; Table 1; Figure 1). Normal controls were used
Table 1 | Identification of C3NeF-containing samples
COS COS-P COIg
HA FPC
Sample Serum Ig Serum Ig Serum Ig Serum Serum
Control mean 14.5 15.8 18.4 26.3 26.6 24.2 13.9 () ve
Control
mean+2 s.d.
33.5 33.7 32.1 37.4 36.7 43.9 17.5
1 15.0 7.3 65.3 84.6 33.4 NA 49.0 () ve
2 44.9 56.2 70.3 115.7 74.4 42.2 NA (+) ve
3 1.9 NA 38.3 NA 22.7 NA 0 (+) ve
4 0.4 5.7 37.7 81.9 23.6 148.6 0 (+)ve
5 68.8 50.4 78.9 113.3 71.0 51.9 0 (+) ve
6 11.4 14.3 65.9 105.0 72.8 47.0 0 (+)ve
7 52.2 52.8 79.2 87.1 105.3 74.4 0 (+) ve
8 0.0 5.4 57.9 26.4 50.9 79.1 58.0 () ve
9 28.0 12.4 57.6 85.0 53.6 33.2 0 (+) ve
10 4.4 4.1 40.3 36.4 64.1 44.1 79 (+)ve
11 21.4 8.9 48.1 36.5 72.2 63.0 47.0 () ve
12 6.1 7.0 43.2 NA 55.5 48.9 39.6 NA
13 88.9 NA 100.3 NA 71.3 NA 6.8 (+) ve
14 14.1 NA 49.4 NA 27.7 NA 51.8 (+) ve
15 10.8 11.5 25.1 38.1 47.8 48.6 28.8 (+) ve
16 10.1 8.5 38.5 74.1 43.8 86.0 15.6 (+) ve
17 20.4 NA 58.9 NA 47.8 NA 21.6 (+) ve
19 78.6 107.0 91.6 101.5 42.7 22.3 89.0 (+) ve
20 108.8 NA 121.7 NA 116.3 NA 85.2 (+) ve
21 96.4 102.4 100.9 98.3 90.0 89.2 83.5 (+)ve
22 11.0 6.8 45.9 80.0 26.2 74.0 83.5 (+) ve
23 100.0 100.0 100.0 100.0 100.0 100.0 52.7 (+) ve
29 109.5 99.0 152.6 86.6 100.6 104.0 54.7 (+) ve
32 78.6 62.4 41.7 92.5 47.2 28.5 NA NA
34 77.0 77.2 107.5 98.4 134.3 117.6 NA (+) ve
38 122.9 117.8 66.6 131.7 146.1 NA 87.9 () ve
42 103.0 NA 75.2 NA 65.9 NA 22.3 (+) ve
47 67.5 NA 45.5 NA 72.3 NA 37.4 () ve
54 4.2 NA 33.4 NA 22.0 NA 0 NA
56 67.7 66.7 89.5 88.6 56.5 142.0 34.6 NA
57 64.3 51.5 90.2 66.4 42.8 110.7 39.4 NA
59 7.6 NA 45.2 NA 33.3 NA 39.6 NA
62 4.3 NA 35.0 NA 58.5 NA 49.0 (+) ve
64 4.6 NA 20.7 NA 63.9 NA 10.8 NA
65 3.8 NA 27.0 NA 76.1 NA 0 NA
70 28.5 NA 27.1 NA 40.9 NA 68.1 NA
73 5.0 NA 20.6 NA 68.6 NA 18.1 NA
74 5.7 NA 25.1 NA 40.3 NA 10.8 NA
81 4.8 NA 36.8 NA 4.8 NA 7.9 NA
84 5.2 NA 35.7 NA 54.4 NA NA (+) ve
85 14.6 NA 54.7 NA 32.3 NA 4.7 NA
86 7.2 NA 17.5 NA 63.5 NA 24.7 NA
89 10.8 NA 27.6 NA 40.8 NA 21.1 NA
91 7.7 NA 19.7 NA 42.1 NA 15.0 NA
92 8.2 NA 31.2 NA 54.1 NA 3.5 NA
93 9.1 NA 30.1 NA 40.8 NA 0 NA
94 4.5 NA 20.6 NA 40.0 NA 1.8 NA
96 6.2 NA 35.8 NA 15.6 NA 24.2 NA
Abbreviations: C3NeF, C3 nephritic factor; ELISA, enzyme-linked immunosorbent
assay; NA, not assayed.
Serum or immunoglobulin (Ig) from patients or healthy donors were tested using
three different ELISAs, which detected (i) stabilization of the convertase without
additional properdin (COS), (ii) stabilization of C3 convertase with additional
properdin, (COS-P); or (iii) binding of C3NeF to the convertase (COIg). In these
ELISAs, activity of C3NeF samples is expressed relative to a highly positive C3NeF
sample (23), which is defined as 100%. Samples were additionally tested by
hemolytic assay (HA), which indirectly detected the presence of C3NeF-stabilized C3
convertase in serum; percent lysis is given. Ability of C3NeF to promote cleavage of
C3 in the fluid phase (FPC) is also shown. Control samples were run in triplicate and
means and upper limits (mean+2 s.d. values) are given in the Table (apart from FPC).
Samples were run in duplicate. Data are only shown from samples that were positive
in one or more test. The results are a single assay set representative of at least two
performed on the samples. Samples in bold are considered to be positive.
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to set detection thresholds (meanþ 2 s.d.) for each assay,
except FPC where results were either positive or negative (all
controls negative) (Table 1). Of 101 samples tested, 48 were
positive in one or more assay. COS-P detected C3NeF in 36 of
101 samples (serum data; Figure 1b). Results, expressed
relative to a chosen ‘standard’, varied up to 5-fold between
samples but were internally consistent in three repeats
(Figure 1; Table 1). COS detected C3NeF in only 16 samples,
all strongly positive in COS-P, implying that properdin
increased detection sensitivity (Figure 1a and b; Table 1).
COIg detected C3NeF in 39 serum samples, 27 of which were
also positive in COS-P but 12 of which were negative in
convertase stabilization assays (Figure 1c; Table 1). Measured
binding in COIg varied enormously between serum samples
and correlated (r¼ 0.5762; Po0.0001) with COS-P (serum).
Twenty-six of 98 patient samples tested in HA were
positive; of these, five were negative in COS-P and five
(different samples) were negative in COIg (Figure 1c; Table 1).
Ten C3NeF ‘missed’ in the HA assay were low positive in
COS-P or COIg assays. Twenty-three of 82 samples tested
were positive in FPC (Figure 1d; Table 1); all of these were
positive in COS-P serum assay, except sample 15, which was
positive when purified IgG was used.
All C3NeF-positive samples were tested for binding
convertase component proteins (C3b, fB, Bb) immobilized
on ELISA plates; no sample gave a reading above background
in the presence of ethylenediaminetetraacetic acid (EDTA) to
block activation on the plate, indicating that all C3NeF
bound neoepitopes in the assembled convertase.
C3NeF prevent C3 convertase regulation
To test whether C3NeF binding affected C3 convertase
regulator binding and control of convertase, an ELISA-based
functional assay was used. Nickel-stabilized C3bBb formed in
the presence of C3NeF was incubated with fH, soluble DAF
(sDAF), or soluble CR1 (sCR1) titrated to cause complete
decay of nickel-stabilized convertase in the absence of C3NeF.
Forty-two of 48 C3NeF tested completely or substantially
(420% residual convertase) prevented fH-mediated
decay; 39 blocked sCR1 decay (34 of which also blocked fH
decay), and 30 blocked sDAF decay (28 of which also blocked
fH; Table 2).
Real-time analysis of C3NeF stabilization of convertase
Representative C3NeF, either highly stabilizing and positive
in COS and COS-P (29 and 21) or weakly stabilizing and
positive only in COS-P (16 and 22), were tested for their
capacity to bind C3bBb by surface plasmon resonance (SPR).
These assays required purified patient IgG at high concentra-
tion and were thus possible only for samples available in
sufficient volume (at least 2ml). fB, fD, and C3NeF IgGs were
flowed over immobilized C3b, and convertase formation and
decay were measured (Figure 2). Binding signal was increased
when fB/fD were flowed in the presence of each C3NeF, but
was much greater for samples 29 and 22 (Figure 2a and d)
compared with samples 21 and 16 (Figure 2b and c).
Increased binding signal in the presence of C3NeF could be a
consequence of either enhanced convertase formation (more
Bb binding C3b) or binding of C3NeF to C3bBb; these events
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Figure 1 |Detection of C3NeF in patient samples. Serum or immunoglobulin (Ig) from patients or healthy donors were tested using
enzyme-linked immunosorbent assay (ELISAs), which detected (a) stabilization of C3 convertase without additional properdin (COS);
(b) stabilization of the convertase with additional properdin (COS-P); (c) binding of C3NeF to the convertase (COIg); or (d) hemolytic assay
(HA), which indirectly detects the presence of C3NeF-stabilized C3 convertase in serum. In the ELISAs, the activity of C3NeF samples is
expressed relative to a highly positive C3NeF sample (23), which is defined as 100%. Mean±s.d. is indicated; normal range (mean of
controlsþ 2 s.d.) is indicated by a dashed line in each assay (a–c). To enable comparison between assays, those patient samples that are
negative in the COS-P assay are colored in gray. COIg, C3NeF Ig-G-binding ELISA; COS, C3 convertase ELISA; COS-P, C3 convertase-properdin
ELISA; C3NeF, C3 nephritic factor; NHIg, Ig from normal healthy donors; NHS, serum from normal healthy donors.
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are influenced by C3NeF concentration, affinity for C3bBb,
and the capacity to prevent decay, which is impossible to
analyze by SPR. Injection of sDAF to remove nonstabilized
enzyme (Figure 2; gray control trace) showed that the
amount of residual stabilized enzyme was much greater for
sample 29 than the other tested C3NeF, but in all cases
stabilized enzyme was resistant to further sDAF decay
(Figure 2). Strongly stabilizing C3NeF markedly extended
C3 convertase half-life (sample 29 42 h; sample 21 44 h),
whereas weakly stabilizing C3NeF increased half-life to a
much less extent (sample 16, 40min; sample 22, 42min;
unstablized convertase B5min). SPR showed that C3NeF
requiring properdin for detection in ELISA (COS negative)
stabilized C3bBb even in the absence of properdin, albeit
much less efficiently than C3NeF detected without added
properdin (COS positive). Properdin-requiring C3NeF likely
cause even greater increased half-life of properdin-stabilized
convertases, which is impossible to test by SPR because
properdin-stabilized convertase was not decayed by DAF and
resisted dissociation by regeneration buffer.
C3NeF binding enhances C3 convertase activity
To investigate whether C3NeF binding altered convertase
C3-cleaving capacity, C3b was immobilized on chip and C3NeF-
stabilized convertase generated by flowing fB, fD, and C3NeF-
IgG representative of the range of characteristics observed
in the samples (strong positive in COS: samples 29 and 21;
positive only in COS-P: samples 16 and 22). Nonstabilized
C3 convertase was decayed by sDAF and residual C3NeF-
stabilized convertase was measured. C3 was flowed for 2min
to deposit nascent C3b covalently on-chip. Chip-bound Bb
and C3NeF were removed by flowing 10mmol/l sodium
acetate, pH 4, 1mol/l NaCl, and newly deposited, covalently
bound C3b on-chip was measured (Figure 3). Control
convertase, formed by flowing fB and fD in the presence of
NHIg (Ig from normal healthy donors), caused deposition of
B2.5 C3b molecules per enzyme resonance unit (RU; Figure
3a; Table 3); convertase stabilized by C3NeF from samples 16
and 22 markedly increased convertase activity (8- to 10-fold
increased C3b binding per enzyme RU); sample 21 increased
C3 deposition 4-fold, whereas sample 29 had little effect on
activity (Table 3).
C3NeF enhances C5 convertase activity
To assess whether C3NeF influenced C5 convertase activity,
C3bBbC3b was assembled on antibody-coated sheep eryth-
rocytes (EA) in the presence of C3NeF-Ig to stabilize
convertase before developing lysis by adding R3 diluted in
EDTA. The absence of active C3 in R3 prevents further C5
convertase formation; lysis therefore measures preformed C5
convertase. Those C3NeF that enhanced C3 convertase
activity (samples 16 and 22; Table 3; Figure 3) also enhanced
lysis in C5 convertase assay, indicating that they increased C5
convertase stability and/or activity; C3NeF samples 29 and 21
had no effect on C5 convertase (Figure 4).
DISCUSSION
C3NeF, autoantibodies against the AP C3 convertase, strongly
associate with chronic AP activation in disease. Involvement
in different pathologies with variable outcomes suggests that
Table 2 | Decay of C3NeF-stabilized C3 convertase by fH,
sDAF, and sCR1
Percentage residual C3 convertase
Sample fH sCR1 sDAF
1 82.1 48.1 50.4
2 82.2 60.6 63.9
3 81.2 0 0
4 81.0 0 0
5 82.3 83.5 90.6
6 82.1 88.5 98.1
7 100.0 80.7 90.8
8 82.0 9.6 3.5
9 81.9 55.7 58.5
10 4.6 0 0
11 55.4 62.8 61.7
12 25.4 0 0
13 100.0 76.0 71.0
14 74.5 32.8 37.6
15 67.3 92.4 99.5
16 46.2 31.3 23.9
17 73.1 26.5 25.0
19 96.2 81.0 70.7
20 99.2 82.0 81.7
21 100.0 73.4 70.8
22 94.9 34.6 35.0
23 85.8 62.6 57.4
29 89.8 72.1 64.7
32 84.5 9.6 9.4
34 79.0 28.0 17.0
38 94.8 75.8 62.8
42 77.9 79.9 79.6
47 46.1 63.0 66.5
54 31.7 32.9 16.1
56 98.1 79.6 74.4
57 93.0 73.1 68.0
59 50.3 14.4 16.1
62 46.3 48.4 44.4
64 32.7 12.8 16.6
65 59.0 25.0 31.5
70 94.4 74.6 77.6
73 20.4 28.4 16.5
74 17.7 35.2 27.0
81 14.6 22.1 12.5
84 3.3 27.5 22.2
85 23.8 27.1 17.8
86 21.5 80.0 80.3
89 11.6 23.5 13.5
91 3.6 24.4 13.0
92 26.9 26.2 12.4
93 24.7 26.3 17.8
94 24.1 9.6 7.8
96 52.4 56.8 47.5
Abbreviations: Bb, larger cleavage fragment of factor B; COS-P, C3 convertase-
properdin enzyme-linked immunosorbent assay; C3NeF, C3 nephritic factor; ELISA,
enzyme-linked immunosorbent assay; fH, factor H; sCR1, soluble complement
receptor 1; sDAF, soluble decay accelerating factor.
The convertase ELISA (COS-P) was adapted to determine whether C3NeF affected
accelerated decay mediated via fH, sDAF, or sCR1. After enzyme formation, plate-
bound convertase was subjected to 20min of accelerated decay prior to detecting
residual convertase with anti-Bb antibody. Results are presented as percent residual
convertase; values above 20% indicate a decay-resistant C3NeF; values below 20%
represent decay-sensitive C3NeF. The results are a single assay set representative of
at least two performed on the samples.
Kidney International (2012) 82, 1084–1092 1087
D Paixa˜o-Cavalcante et al.: Functional assays for C3 nephritic factors o r ig ina l a r t i c l e
C3NeF are heterogeneous, binding and influencing C3bBb
function and regulation in diverse ways. C3NeF levels
fluctuate in individuals with time and do not correlate with
disease.16 Confusion over their clinical relevance is, in
part, because they are difficult to measure. Current assays
are complicated, laborious, require expertise, and scarce
reagents, and prone to artifact. Methods are inconsistent
between laboratories and there is no national/international
quality control.
To address these problems and identify optimal assays for
routine detection of C3NeF, a panel of assays was established
and optimized to identify C3NeF in patient samples. The
COS-P assay, measuring the capacity of C3NeF to prolong
half-life of properdin-stabilized C3bBb, was reproducibly
positive in 36 of 101 samples, albeit with a wide range of
values. In the absence of added properdin (COS), only 16 of
101 samples were positive, all of these were strongly positive
in COS-P, indicating that these assays differed in sensitivity,
and that additional stability conferred by properdin enabled
detection of weaker binding C3NeF. The COIg assay,
measuring binding of C3NeF IgG to nickel-stabilized
convertase, was positive in 39 of 101 samples, 27 of which
were positive in COS-P. The assays showed a strong
correlation, but each assay alone missed some C3NeF, which
was positive in the other assay. The COIg assay will miss any
non-IgG C3NeF; we explored this possibility in those COS-P-
positive samples negative in COIg using commercial anti-
IgM, but, without a positive control, were unable to obtain
reproducible results. The HA assay was positive in 26 of 98
samples tested; all HA positives were also positive in COS-P
and/or COIg, suggesting that HA was specific but insensitive,
missing many C3NeF detected by other assays. The FPC was
positive in 23 of 82 samples tested, all also positive in COS-P
and/or COIg, demonstrating specificity but insensitivity. HA
and FPC missed different C3NeF and not all missed samples
were of low activity in COS-P and COIg. No C3NeF bound
individual convertase components, demonstrating specific
recognition of neoepitopes in intact convertase.
By SPR, purified IgGs from two samples strongly positive
in all three ELISAs bound C3bBb to create highly stable
convertases with half-lives in excess of 2 h (unstabilized half-
life being 5min), whereas IgGs from samples weakly positive
in COS-P and COIg and negative in COS caused 8-fold
increase in convertase half-life. Several reports suggest that
C3NeF block accelerated decay.20–22,25 Almost all C3NeF
tested here blocked accelerated decay of the convertase by fH,
sDAF, and sCR1; only 6 of 48 C3NeF tested failed to
significantly inhibit fH decay, whereas 18 failed to inhibit
decay by sDAF and 9 decay by sCR1. Inhibition of accelerated
decay was confirmed by SPR. Most C3NeF therefore have
dual actions, preventing both spontaneous and accelerated
decay. C3NeF sensitive to regulation by fH and other
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Figure 2 | Sensorgram illustrating real-time C3 convertase formation in the presence of C3NeF-containing IgG. C3 convertase was
formed by flowing 40 ml of a mix containing factor B (180 mg/ml) and factor D (1 mg/ml) in the presence of C3NeF-containing IgG (400 mg/ml,
black line) or normal human IgG (gray line) over C3b immobilized on a CM5 Biacore chip (IgG from (a) sample 29, (b) sample 21, (c) sample
16, (d) sample 22). The convertase was left to spontaneously decay for 100 s before injecting 20 ml of sDAF (8 mg/ml) across the surface.
Notice that active larger cleavage fragment of factor B subunit is completely decayed away when C3 convertase is formed in the presence of
Ig from normal healthy donors, and that in the presence of C3NeF varying amounts of C3 convertase remained bound to the surface. In all
cases, the C3bBb–C3NeF remaining on the surface was very stable; decay curve indicated by asterisk. Half-life after removal of nonstabilized
enzyme is calculated as ln2/kd. C3NeF, C3 nephritic factor; IgG, immunoglobulin G; RU, resonance unit; sDAF, soluble decay accelerating
factor.
1088 Kidney International (2012) 82, 1084–1092
or ig ina l a r t i c l e D Paixa˜o-Cavalcante et al.: Functional assays for C3 nephritic factors
regulators are likely less pathogenic in vivo; indeed, one
report showed that fH-sensitive C3NeF are not associated
with hypocomplementaemia, implying that fluid-phase
activation is controlled.25 C3NeF that are fH-resistant but
DAF and/or CR1-sensitive likely mediate effects in the fluid
phase, leading to different pathologies; these are excellent
targets for therapy using recombinant sCR1 and/or DAF.26–28
To cause pathology, C3NeF-stabilized convertase must
retain its capacity to cleave C3. This was demonstrated by
SPR for four selected C3NeF IgGs. Each C3NeF-stabilized
convertase cleaved C3 and deposited C3b on the chip;
however, convertases stabilized by strongly binding C3NeF
were much less efficient C3 cleavers than convertases
stabilized by weak-binding C3NeF. These findings illustrate
heterogeneity and suggest that pathological consequences
cannot be predicted by strength of binding; strong binders
may reduce efficiency of the enzyme by restricting engage-
ment with substrate. Structural analyses of convertase–C3NeF
complexes are needed to test these contentions.
A subset of C3NeF enhance C5 cleavage and terminal
pathway activation.29,30 The same four C3NeF IgGs used in
SPR analysis were tested in HAs designed to interrogate C5
convertase stabilization and/or activity. Two caused enhanced
lysis via the terminal pathway, whereas the other two did not.
Those C3NeF causing enhanced lysis were ‘weak’ C3
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Figure 3 |Real-time analysis of C3NeF-stabilized C3 convertase activity. C3 convertase was formed by flowing factor B (fB) and factor D
in the presence of 400 mg/ml of C3NeF-containing IgG (from (b) sample 29, (c) sample 21, (d) sample 16, (e) sample 22) or normal human
IgG (NHIg, (a)) over the amine-coupled C3b. Where C3NeF was included, all nonstabilized C3 convertase was decayed by sDAF. The enzyme
substrate, C3 (200 mg/ml), was flowed across the surface, resulting in covalent deposition of C3b onto the chip surface. Bound Bb and C3NeF
were removed with 10mmol/l sodium acetate pH 4/1mmol/l NaCl (‘Reg’), and the amount of C3b covalently bound to the surface was
measured. Asterisk indicates C3bBb–C3NeF complex remaining on surface after removal of nonstabilized convertase. Bb, larger cleavage
fragment of factor B; C3NeF, C3 nephritic factor; fB, factor B; IgG, immunoglobulin G; NHIg, Ig from normal healthy donors; RU, resonance
unit; sDAF, soluble decay accelerating factor.
Table 3 | Activity of the C3NeF-stabilized C3 convertase as
assessed by C3b deposition on the surface of a Biacore chip
Sample
Amount of
C3bBb–C3NeF
complex (RU)
Calculated
amount of
Bba (RU)
C3b deposited
on the
chip (RU)
Ratio of
C3b/Bb bound
on the chip
NHIg 64 64 (no C3NeF) 167 2.6
29 169 49 92 1.9
21 49 14 127 9.1
16 33 9 246 27
22 46 13 255 20
Abbreviations: Bb, larger cleavage fragment of factor B; C3NeF, C3 nephritic factor;
IgG, immunoglobulin G; NHIg, Ig from normal healthy donors.
C3NeF-stabilized convertase was formed on the surface of a Biacore chip and
substrate, C3, was flowed across for 120 s. C3NeF and bound Bb were removed with
regeneration buffer and amount of nascent C3b deposited on the chip surface per
resonance unit (RU) of Bb comprising the convertase was calculated.
aAmount of Bb present=(total RU 60)/(60+150). This assumes mass of Bb is 60 kDa,
mass of IgG 150 kDa and a 1:1 complex of Bb and IgG is formed. The results are from
a single experiment representative of at least two performed on the samples.
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convertase binders, requiring extra properdin or nickel for
detection, with short stabilized half-lives, and efficient C3
cleavers.
While this manuscript was in review, a report appeared
describing the development of assays for C3NeF.31 Patients
with biopsy-proven DDD were screened for C3NeF using
C3NeF assays comprising an ELISA measuring IgG binding
immobilized convertase that resembled COIg, except without
added properdin, and erythrocyte-based convertase-stabiliza-
tion assays with or without properdin resembling COS and
COS-P, respectively, except that the end point was hemolysis.
These were compared with ‘traditional’ assays based on
activation, immunoelectrophoresis, and immunofixation,
which resembled FPC. The convertase-stabilization assays
required serum depleted of fH, which must be prepared fresh
because it rapidly autoactivates, restricting these assays to
specialist complement laboratories; in contrast, our plate-
based assays require no specialist reagents and are readily
translatable to routine use. Of 32 DDD patients screened,
53% were positive in IgG-binding ELISA, 69% in C3
convertase stabilization without properdin, and 78% in the
presence of properdin; the ‘traditional’ assays detected C3NeF
in 69%. These data support our finding that optimal assays
for C3NeF involve measurement of IgG binding to convertase
or stabilization of properdin-stabilized convertase. Impor-
tantly, both studies demonstrate that, even with optimized
assays, not all patients with a presumptive or confirmed
diagnosis have detectable C3NeF; more work is needed to
explore whether these patients harbor unusual C3NeF missed
in the available assays.
We confirm previously noted heterogeneity of C3NeF,
describe convertase-stabilizing activity and other activities
of selected C3NeF, and provide assays for C5 convertase
stabilization. We deliberately abandon terms and subgroups
used historically to categorize C3NeF, instead stressing that
each C3NeF must be treated as a unique entity with
properties that predicate its pathological effects. We show
that simple ELISA for convertase stabilization and/or binding
is most reliable for C3NeF detection. We propose a rational
approach in which serum samples from patients presenting
with relevant history are first screened for AP activation using
standard assays (C3, C4, fB, hemolytic activity (CH50;
AP50), activation markers such as terminal complement
complex where available). Where AP activation is identified
(low C3, fB, AH50; elevated terminal complement complex),
samples are screened for C3NeF using COS-P, which
identifies most C3NeF. Clinically suspicious samples negative
in COS-P are screened in COIg, which detects weakly or
nonstabilizing C3NeF missed in COS-P. Serum samples
negative in COIg are rescreened using purified IgG to detect
fH-sensitive C3NeF that can be missed in serum. Where
appropriate, positive samples are further screened in
specialist centers to identify those conferring resistance to
fH regulation or stabilizing C5 convertase.
MATERIALS AND METHODS
Samples
Sera from 101 patients presenting with histological and/or clinical
evidence suggesting DDD (480%), membranoproliferative glomer-
ulonephritis Type I, proliferative glomerulonephritis, cortical necro-
sis, systemic lupus erythematosus, or vasculitis were collected with
local ethical approval. All sera were screened at the source for
evidence of AP activation (low C3, low fB, low AP50 ± elevated
terminal complement complex), and only AP activation–positive sera
were included. Control sera were obtained from 25 healthy controls
(Cardiff University Research Ethics Committee Ref. 10/26). To purify
C3NeF-IgG, serum was applied to Protein G (GE Healthcare, Little
Chalfont, UK) equilibrated with phosphate-buffered saline (PBS).
Bound IgG was eluted using 0.1mol/l glycine, pH 2.5, and dialyzed
into PBS. Control IgG was purified from C3NeF-negative serum.
Complement components and antibodies
C3 was prepared by classical chromatography, and fB and fH by
affinity chromatography as described.32,33 C3b and Bb were prepared
from these reagents by AP activation as described.32 Protein con-
centrations were derived from A280 (fH: 1.95 cm
1(mg/ml)1, fB:
1.43 cm1(mg/ml)1; C3: 0.98 cm1(mg/ml)1; Ig: 1.4 cm1(mg/ml)1.
FD and properdin were from Complement Technology (Tyler, TX).
Soluble recombinant DAF (sDAF) was from Professor S. Lea (University
of Oxford); soluble recombinant CR1 (sCR1) was from T Cell Sciences
(Needham, MA). Rabbit polyclonal anti-fB was from Complement
Technology. Peroxidase-conjugated secondary antibodies were from
Jackson Immunoresearch (West Grove, PA). R3 was generated by
treating plasma with hydrazine (50mmol/l, pH 8.5) for 2 h at 37 1C
followed by dialysis against PBS, 20mmol/l EDTA.
C3NeF stabilization ELISA with (COS-P) and without (COS)
properdin
ELISA plates (Medisorb, Nunc, VWR, Lutterworth, UK) were coated
with C3b (1 mg/ml in PBS, 1 h, room temperature), blocked in PBS/
1% bovine serum albumin, and washed in assay buffer (2.5mmol/l
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Figure 4 | Effect of C3NeF on terminal pathway. C5 convertase
was assembled on the surface of sheep E by incubating antibody-
coated sheep erythrocytes-C3b with factor B (fB), factor D, and
C3NeF-containing immunoglobulin (Ig; samples 16, 21, 22, or 29)
or NHIg. Lysis was developed by incubating cells with serum/
ethylenediaminetetraacetic acid lacking active C3 (R3). Only C5
convertase formed in the first step was able to trigger lysis, as no
further C3 could be cleaved. Lysis of cells was measured by
release of hemoglobin. Samples are identified as follows: sample
16 (K); sample 21 (’); sample 29 (&), sample 22 (J), or NHIg
(n). NHIg, Ig from normal healthy donors.
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sodium barbitone, pH 7.4, 71mmol/l NaCl, 0.15% Tween, 1mmol/l
MgCl2). Convertase was formed by adding 50 ml test serum (1/50 in
assay buffer) or purified Ig (50 mg/ml), immediately followed by
50 ml of a mixture comprising fB (1 mg/ml) and fD (0.2 mg/ml) with
(COS-P) or without (COS) properdin (0.5 mg/ml) in assay buffer.
After 30min at 37 1C, plates were washed in assay buffer and
residual Bb detected using goat anti-fB (1:1000; 1 h, 37 1C), followed
by peroxidase-conjugated donkey anti-sheep Ig (1:5000; 1 h). Color
was developed using o-phenylenediamine dihydrochloride (Sigma-
Aldrich, Poole, UK). Assay blank was obtained by omitting fB and
serum/Ig; a sample known to be strongly positive for C3NeF was
used as positive control and results expressed relative to this:
percentage of stabilization¼ 100 (A492 testA492 blank)/(A492
C3NeF-positive controlA492 blank). In some experiments, con-
vertase was formed in the presence of 1mmol/l NiSO4 to stabilize,
plates were washed and incubated with 100 ml fH (15 mg/ml), sDAF
(5mg/ml), or sCR1 (10 mg/ml) in assay buffer at room temperature
for 20min before the measurement of residual Bb. Percentage decay
was calculated as 100 [(A492 test sample in absence of the
complement regulatory protein (CReg)–A492 of blank)(A492 test
sample in presence of the CReg–A492 of blank)]/(A492 test sample in
absence of CRegA492 blank). Percent residual convertase is 100
minus percent decay.
C3NeF-binding ELISA (COIg)
To test binding of C3NeF to preformed convertase, ELISA plates
were coated with C3b and convertase formed by incubation with fB
(1mg/ml), fD (0.2 mg/ml), properdin (0.5 mg/ml), and sample as
described above, except that assay buffer contained 1mmol/l NiSO4.
Plates were washed and bound Ig detected using peroxidase-labeled
anti-human IgG (1:5000). A strongly positive C3NeF sample was
used as positive control. Background was obtained by omitting fB,
fD, and serum/Ig. Absorbance was measured at 492 nm, and bound
C3NeF calculated as 100 (A492 test sampleA492 blank)/(A492
C3NeF positive controlA492 blank).
C3NeF fluid-phase C3 cleavage assay
Equal volumes of test serum, NHS (serum from normal healthy
donors), and assay buffer (2.5mmol/l sodium barbitone pH 7.4,
71mmol/l NaCl, 0.15% Tween, 7mmol/l MgCl2, 20mmol/l ethylene
glycol bis(b-aminoethylether)-N,N,N’,N’,-tetraacetic acid) were mixed
and incubated (37 1C, 3 h). Cleavage of C3 was detected by western
blot using rabbit polyclonal anti-human C3 (in-house). Controls
included NHS and patient serum, incubated as described above, in
the presence of 20mmol/l EDTA. Results were expressed as positive
(significant C3 cleavage) or negative (no C3 cleavage above controls).
C3NeF HA
Sheep erythrocytes (1.5 107/ml in AP buffer; 5mmol/l sodium
barbitone, pH 7.4, 150mmol/l NaCl, 7mmol/l MgCl2, 10mmol/l
ethylene glycol bis(b-aminoethylether)-N,N,N’,N’,-tetraacetic acid)
were incubated with a mixture containing equal amounts of NHS
and patient serum for 10min at 30 1C.34 Cells were washed and
incubated for 1 h at 37 1C with rat serum diluted 1:10 in PBS/
20mmol/l EDTA to develop lysis. Cells were centrifuged and
absorbance in supernatant measured at 410 nm. As controls, cells
were incubated with AP buffer (0% lysis) or 0.01% Triton X-100
(100% lysis). Percentage lysis was calculated as follows: 100 (A410
test sampleA410 0% control)/(A410 100% lysisA410 0% control).
C3NeF binding to immobilized C3b, fB, or Bb
ELISA plates (Medisorb, Nunc) were coated with C3b, fB, or Bb at
1 mg/ml, blocked in PBS/1% bovine serum albumin, and then
incubated with 50 ml of C3NeF-positive test serum diluted 1/50 in
assay buffer containing 20mmol/l EDTA. Plates were washed and
C3NeF binding detected using peroxidase-conjugated anti-human
IgG (1:5000). Each incubation period was for 1 h at 37 1C. Color was
developed as above and absorbance measured at 492 nm.
Stabilization and activity of convertase assessed by SPR
SPR analyses required sufficient patient IgG to flow at high
concentrations, and thus was limited to samples in which adequate
volume was available for IgG purification. To measure stabilization,
C3 convertase was formed on-chip by flowing fB (180 mg/ml) and fD
(1mg/ml) over immobilized C3b (700 RU) with NHIg or C3NeF-
IgG (400 mg/ml) in Biacore buffer (10mmol/l HEPES, pH 7.4,
150mmol/l NaCl, 1mmol/l MgCl2, 0.005% surfactant P20).
Convertase was left to spontaneously decay for 100 s, and 20ml of
sDAF (8mg/ml) was injected to decay nonstabilized convertase. The
half-life (t1/2) of C3NeF-stabilized convertase was estimated from
dissociation rate (kd) (t1/2¼ ln2/kd). To measure activity, convertase
was formed on-chip as above; nonstabilized enzyme was decayed by
flowing sDAF. C3 (200 mg/ml in Biacore buffer) was flowed; nascent
C3b bound covalently to the surface as described.33 Residual Bb and
C3NeF were removed by flowing 10mmol/l sodium acetate, pH 4,
1mol/l NaCl, and deposited C3b was measured using the
BiaEvaluation 4.1 software.
C3NeF-stabilized terminal pathway activity
Antibody-sensitized ShE (EA) were prepared by incubating 2% ShE
with amboceptor (1:4000, 30min, 37 1C; Siemens Healthcare,
Erlangen, Germany); EA were washed into complement fixation
diluent (CFD; Oxoid, UK), and C3b deposited by incubating with
fB- and fH-depleted serum containing the C5 inhibitor, OmCI, as
described.35 EAwere resuspended to 2% (v/v) in AP buffer (5mmol/
l sodium barbitone, pH 7.4, 150mmol/l NaCl, 7 mmol/l MgCl2,
10mmol/l ethylene glycol bis(b-aminoethylether)-N,N,N’,N’,-
tetraacetic acid), and 50-ml aliquots were incubated with
dilutions of fB and 0.5 mg/ml fD in the presence or absence of
C3NeF-IgG (100 mg/ml; 15min, 37 1C) to form C5 convertase.
Lysis was developed by adding 50 ml R3 diluted 1:25 in PBS,
20mmol/l EDTA.
Statistics
Unpaired t-test with Welch’s correction was used for inter-group
comparison. Data were analyzed using GraphPad Prism 3.0
(GraphPad, San Diego, La Jolla, CA).
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